Acetaminophen or NSAIDs for the treatment of osteoarthritis

被引:35
作者
Bannwarth, B [1 ]
机构
[1] Univ Bordeaux 2, Hop Pellegrin, Dept Rheumatol, F-33076 Bordeaux, France
[2] Univ Bordeaux 2, Div Therapeut, EA 525, F-33076 Bordeaux, France
来源
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2006年 / 20卷 / 01期
关键词
osteoarthritis; pain; non-steroidal anti-inflammatory drugs; coxibs; topical treatment; acetaminophen;
D O I
10.1016/j.berh.2005.09.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Although non-pharmacological interventions are the cornerstone of osteoarthritis management, analgesics are an important component of treatment during the symptomatic periods of the disease, In this respect, current practice guidelines advocate the use of a simple analgesic, acetaminophen, or a non-steroidal anti-inflammatory drug (NSAID), given either systemically or topically as first-line or second-line drug therapies. The present paper aims first to assess the evidence for the efficacy and safety of these medications. Given the increasing importance of patient involvement in decision-making, the following key practical issue regarding acetaminophen and NSAIDs will then be addressed: 'which drug do patients prefer?' Regarding NSAIDs, a further question concerns the place for non-selective agents and cyclo-oxygenase-2 (COX-2) selective inhibitors (coxibs) in the light of new warnings and contraindications concerning coxibs in patients with increased risk of cardiovascular thrombotic events.
引用
收藏
页码:117 / 129
页数:13
相关论文
共 59 条
[1]   Et tu, acetaminophen? [J].
Abramson, SB .
ARTHRITIS AND RHEUMATISM, 2002, 46 (11) :2831-2835
[2]  
Altman RD, 2000, ARTHRITIS RHEUM-US, V43, P1905
[3]   Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure [J].
Aw, TJ ;
Haas, SJ ;
Liew, D ;
Krum, H .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (05) :490-496
[4]   Photosensitivity to ketoprofen - Mechanisms and pharmacoepidemiological data [J].
Bagheri, H ;
Lhiaubet, V ;
Montastruc, JL ;
Chouini-Lalanne, N .
DRUG SAFETY, 2000, 22 (05) :339-349
[5]   Do selective cyclo-oxygenase-2 inhibitors have a future? [J].
Bannwarth, B .
DRUG SAFETY, 2005, 28 (03) :183-189
[6]   Pharmacological rationale for the clinical use of paracetamol:: Pharmacokinetic and pharmacodynamic issues [J].
Bannwarth, B ;
Péhourcq, F .
DRUGS, 2003, 63 :5-13
[7]  
Bannwarth Bernard, 2004, Expert Opin Drug Saf, V3, P269, DOI 10.1517/14740338.3.4.269
[8]   Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in ostcoarthritic knee pain: meta-analysis of randomised placebo controlled trials [J].
Bjordal, JM ;
Ljunggren, AE ;
Klovning, A ;
Slordal, L .
BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7478) :1317-1320D
[9]   Effects of NSAIDs on the incidence of hospitalisations for renal dysfunction in users of ACE inhibitors [J].
Bouvy, ML ;
Heerdink, ER ;
Hoes, AW ;
Leufkens, HGM .
DRUG SAFETY, 2003, 26 (13) :983-989
[10]   Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis [J].
Chan, FKL ;
Hung, LCT ;
Suen, BY ;
Wu, JCY ;
Lee, KC ;
Leung, VKS ;
Hui, AJ ;
To, KF ;
Leung, WK ;
Wong, VWS ;
Chung, SCS ;
Sung, JJY .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (26) :2104-2110